The company has an extensive patent portfolio covering extraction and preservation of DNA and RNA for downstream processing by qPCR, RT-qPCR and sequencing. Arcis launched Arcis Sample Prep and Arcis Blood kit in 2016, with a Pathogen kit launched in 2017, and further new product launches planned for 2018. Arcis offers a quick, simple, low resource option in comparison to existing technologies on the market – making it ideal for point of care or field based testing. Arcis has been awarded Innovate grants for detection of nucleic acid material from plants and the  company has recently been awarded a Biocatalyst feasibility grant to stabilise RNA from urine which is anticipated will lead to a simpler and more convenient diagnostic test for prostate cancer from urine and eliminate the need for an invasive examination. Arcis is also working closely with a number of molecular pathogen testing companies to integrate the Arcis extraction technology into their chemistry and detection processes.

Paul Foulger - Non-Executive Chairman

Paul is a qualified certified accountant with extensive public and private company experience. He has substantial lead transactional
experience in cluding IPO's, cash shells, reverse takeovers, divestments,over £100m of fundraising, and a number of acquisitions
both in the UK/Europe and the US. He is also a non-exec director of Jupiter Diagnostics, a Point-of-Care blood diagnostics business.

Peter Whitehurst - CEO

Peter joined Arcis in March 2011. A Qualified Chartered Accountant with Ernst Young by background and prior global roles with Cable
& Wireless and Fortune Brands Inc. Peter was a key member of the Executive Team of SSL International leading the Innovation &
Technology teams, and was heavily involved in the trade sale of SSL to Reckitt Benckiser for £2.54 billion in late 2010.

Dr Jan Rogers - CSO

Jan joined Arcis in March 2011 and has extensive knowledge of the development and commercialisation of innovative medical
devices.She has held senior R&D positions at London International Group, Regent Medical, Molnlycke Healthcare, Convatec Inc and
SSL International before joining Arcis Biotechnology. Jan has a PhD in Surface Chemistry from the University of Reading and an MBA
specializing in Innovation from the University of Bath.

The Arcis technology has received a great deal of interest in a wide range of markets ranging from human pathogen, biodefense,  clinical research, veterinary diagnostics, plant genomics and food safety. This has resulted in a number of successful collaborations. If you would like to collaborate with Arcis Biotechnology or look at integrating our products into your workflow please contact us.

Arcis Biotechnology’s main investor –Calculus- invested in Arcis Biotechnology due to their impressive suite of technologies and the wide range of potential applications in different markets.

Arcis is headed by Peter Whitehurst, CEO, and Dr Jan Rogers, CSO, both previously key members of the SSL International executive team prior to its sale to Reckitt Benckiser for £2.54bn in 2010.

Arcis are looking to raise up to £3.0m equity investment. We have already raised £1.25m in this round, from existing and new investors, at a pre-money evaluation of £18.2m

If you would like to invest in Arcis Biotechnology please contact Peter Whitehurst peter.whitehurst@arcisbio.com.